Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of ...
The actor tells AARP about her mom’s struggle with pulmonary fibrosis and the warning signs that might help others get an ...
DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...
Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval ...
Columnist Kylene Henderson and her husband, Donnie, who has PF, swapped caregiver roles after Kylene was injured in a recent ...
In idiopathic pulmonary fibrosis (IPF), the trajectory of declining lung function and clinical worsening was less drastic with the use of inhaled treprostinil (Tyvaso), the placeb ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
Two pivotal Phase 3 trials of Haduvio are expected to launch this year and, if positive, may support applications seeking its ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic coughFirst pivotal ...
Background Pulmonary fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population.
(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cough in Idiopathic Pulmonary Fibrosis pipeline constitutes 5+ key companies continuously working ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results